In an anticlimactic move, mere weeks before its official start, the genomics X Prize – intended to spur a revolution in fast, cheap and accurate human-genome sequencing – has been abruptly cancelled, because it was “outpaced by innovation.”
The prize challenged companies to design devices that could sequence 100 human genomes in 30 days or less, with additional requirements for accuracy and cost. Today, companies are routinely sequencing human genomes for less than the $10,000 per genome goal.
But the full picture is more complex. Yes, the cost of genome sequencing has plummeted, (the prize dropped its cost goal to $1000 per genome in response). But current technologies are still far from meeting the accuracy goal.
Related on the SLP
Read the full, original story here: X Prize for genomes cancelled before it begins
Additional Resources:
- “Outpaced by Innovation: Canceling an XPRIZE,” Huffington Post
Chairman and CEO of the X Prize Foundation, Peter Diamandis, explained the rationale for the cancelation in a Huffington Post column. - “Tepid showing for genomics X prize,” Nature
In May, Nature told the story of the sparse list of competition applicants and the difficulty of driving down the number of inaccuracies in a sequenced genome.





















